Genomic deletion in African swine fever vaccine allowing efficient growth in stable cell lines
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsDouglas P. Gladue, Manuel V. Borca
Life of this patent
Estimating the term…
Abstract
Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.
Claims16
A genetically modified virus, wherein the virus genome comprises a viral genome at least 95% identical to SEQ ID NO:
- 1.
A recombinant ASFV mutant virus, comprising a genome with a deletion, or partial deletion of each of ORFs MGF360-4L, MGF360-6L, X69R, MGF300-1L, MGF300-2R, MGF300-4L, MGF3608L, MGF360-9L, MGF360-10L, and MGF360-11L.
Dependencies are inferred from the claim text.